ReviewTrends in neurosciences2024
Examining resilience to Alzheimer's disease through the lens of monoaminergic neuromodulator systems.
Review in Trends in neurosciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Cognitive markers of resilience to dementia in mild Neurocognitive Impairment: a meta- analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Pooled it
- Brain structure in the cingulate cortex and locus coeruleus in late life is associated with engagement in complex mental activities across the life span.Neurobiology of aging · 2026Article
- Vulnerability of locus coeruleus connections to aging and Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Dopamine Compensates for Amyloid-Induced Default Mode Network Dysfunction to Support Learning.bioRxiv : the preprint server for biology · 2026Article
- 10-year longitudinal dopamine D2-receptor losses are associated with cognitive decline in healthy aging.Cerebral cortex (New York, N.Y. : 1991) · 2025Article
- Defining the contributions of tau pathology in the amygdala to increasing depressive symptoms in aging.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Clustering Cortical Rhythms: Monoaminergic Signatures in Time-Frequency EEG Dynamics.Biomedicines · 2025Article
- Functional and Regional Specificity of Noradrenergic Signaling for Encoding and Retrieval of Associative Recognition Memory in the Rat.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The monoaminergic nuclei are thought to be some of the earliest sites of Alzheimer's disease (AD) pathology in the brain, with tau-containing pretangles appearing in these nuclei decades before the onset of clinical impairments. It has increasingly been recognized that monoamine systems represent a critical target of investigation towards understanding the progression of AD and designing early detection and treatment approaches. This review synthesizes evidence across animal studies, human neuropathology, and state-of-the-art neuroimaging and daily life assessment methods in humans, which demonstrate robust relationships between monoamine systems and AD pathophysiology and behavior. Further, the review highlights the promise of multimethod, multisystem approaches to studying monoaminergic mechanisms of resilience to AD pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.